Key facts
- Solasta Bio’s last known valuation is $32.4M.
- It has raised $20.2M; the latest was Early Stage VC ($13.9M) in Aug 2024.
- Notable investors include Innovate UK, Scottish Enterprise, Future Planet Capital, StartLife, UK Innovation & Science Seed Fund — 17 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 17 names
- ·Watchlist + deal alerts for Solasta Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Solasta Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Solasta Bio
Developer of biological pesticides and insect control products designed to provide superior natural crop protection. The company's product portfolio includes biological pesticides and neuropeptide-based insect control products that control a wide spectrum of pests, including those resistant to synthetic chemistries, enabling farmers to manage pests and insects and improve crop production in a safe, sustainable and eco-friendly manner.
- Sector
- Materials and Resources
- HQ
- Glasgow, United Kingdom
- Founded
- 2020
- Employees
- 37
- Website
- solastabio.com/
- Ownership
- Privately Held (backing)
Solasta Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Solasta Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Solasta Bio in its N-PORT filings yet. We sweep new filings monthly.